Janus Henderson Group PLC Buys 2,719,615 Shares of Avantor, Inc. (NYSE:AVTR)

Janus Henderson Group PLC increased its holdings in shares of Avantor, Inc. (NYSE:AVTR) by 18.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,692,705 shares of the company’s stock after acquiring an additional 2,719,615 shares during the period. Janus Henderson Group PLC owned about 2.60% of Avantor worth $457,710,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Sound Shore Management Inc. CT bought a new stake in shares of Avantor during the second quarter worth approximately $76,412,000. Seven Eight Capital LP purchased a new stake in shares of Avantor during the 2nd quarter worth approximately $642,000. New York State Teachers Retirement System purchased a new position in Avantor in the 3rd quarter valued at approximately $8,473,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of Avantor by 35.1% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,157,855 shares of the company’s stock worth $24,547,000 after acquiring an additional 300,579 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new position in shares of Avantor during the second quarter valued at about $952,000. 95.08% of the stock is currently owned by institutional investors.

Avantor Stock Up 0.1 %

NYSE AVTR opened at $21.09 on Tuesday. The firm has a market cap of $14.35 billion, a PE ratio of 45.85, a P/E/G ratio of 2.55 and a beta of 1.29. Avantor, Inc. has a 52 week low of $19.59 and a 52 week high of $28.00. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The business’s fifty day simple moving average is $23.28 and its 200-day simple moving average is $23.71.

Analyst Ratings Changes

Several research analysts have weighed in on AVTR shares. Robert W. Baird decreased their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Royal Bank of Canada restated an “outperform” rating and set a $34.00 price objective on shares of Avantor in a research report on Thursday, September 26th. Wells Fargo & Company decreased their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. UBS Group cut their price objective on shares of Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, October 8th. Finally, Barclays decreased their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $27.57.

Insider Buying and Selling at Avantor

In related news, CAO Steven W. Eck sold 3,525 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the sale, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. This represents a 10.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.30% of the stock is owned by corporate insiders.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.